Paper Details

  1. Home
  2. Paper Details

Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.

Author: Alegre-Del ReyEmilio, Camean-CastilloManuel, Fenix-CaballeroSilvia, Gimeno-BallesterVicente, Rios-SanchezEsmeralda, Vázquez-RealMiguel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study compared the effectiveness of different treatments for rheumatoid arthritis (RA), including biological DMARDs (disease-modifying antirheumatic drugs) used alone or with methotrexate, and tofacitinib, an oral medication that blocks certain proteins involved in inflammation. The study aims to determine which treatment options are most effective for patients with RA who don't respond well to traditional DMARDs.
Paper Details　
Original Abstract of the Article :
Rheumatoid arthritis (RA) is an autoimmune disease characterized primarily by inflammation and pain in the joints. Tofacitinib is an oral drug recently approved for RA treatment; it inhibits Janus protein kinases (JAK) that reduces RA symptoms when conventional DMARDs do not trigger a response. This...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jcpt.12795

データ提供：米国国立医学図書館（NLM）

Comparing Tofacitinib to Biologic Treatments for Rheumatoid Arthritis

Navigating the vast desert of rheumatoid arthritis (RA) treatment can be challenging, with many different medications available. This research focuses on tofacitinib, an oral drug that inhibits Janus protein kinases (JAK), and compares its efficacy to biologic treatments in patients with moderate-to-severe RA. The authors conducted a network meta-analysis, comparing the effectiveness of different treatments in a comprehensive manner, seeking to provide valuable insights for healthcare professionals and patients.

Understanding the Landscape of RA Treatment Options

This research provides a valuable comparative overview of tofacitinib and biologic treatments for RA. By analyzing data from multiple studies, the authors offer insights into the relative effectiveness of different treatment options. This information can be helpful for healthcare professionals in making informed decisions about treatment strategies and for patients seeking the most effective treatment for their individual needs.

Implications for RA Treatment Decisions

For patients with RA, this research highlights the importance of considering a range of treatment options. While tofacitinib offers a convenient oral therapy, biologic treatments may be more effective for certain patients. Open communication with healthcare providers, a thorough understanding of individual factors, and a comprehensive assessment of treatment goals are essential for making informed decisions about the most appropriate treatment strategy.

Dr. Camel's Conclusion

The desert of rheumatoid arthritis treatment is vast and complex, with many different pathways to navigate. This research provides valuable insights into the landscape of treatment options, empowering both healthcare professionals and patients to make informed decisions. Just as a desert explorer relies on a map and compass, we must continue to explore new research and seek the most effective treatment strategies for those living with RA.

Date :
  1. Date Completed 2019-08-19
  2. Date Revised 2019-08-19
Further Info :

Pubmed ID

30729557

DOI: Digital Object Identifier

10.1111/jcpt.12795

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.